全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

Targeting the Endocannabinoid System in Burning Mouth Syndrome: A Case Report on CBD-Dominant Cannabis Oil

DOI: 10.4236/oalib.1113432, PP. 1-6

Subject Areas: Anaesthesiology & Pain Management

Keywords: Burning Mouth Syndrome, Endocannabinoids, CBD

Full-Text   Cite this paper   Add to My Lib

Abstract

Burning Mouth Syndrome (BMS) is a chronic orofacial pain disorder characterized by burning sensations of the oral mucosa without evident causative lesions. Current treatment options often provide limited relief, highlighting the need for alternative therapeutic approaches. Recent evidence suggests that dysregulation of the endocannabinoid system plays a role in BMS patho- physiology, with altered expression of cannabinoid receptors in oral mucosa. We present a case of a 62-year-old postmenopausal female with a 3-year history of BMS refractory to conventional treatments including topical clonazepam, gabapentin, and alpha-lipoic acid. The patient was treated with CBD-dominant cannabis oil (20:1 CBD:THC ratio), starting at 5 mg CBD twice daily and titrated to 15mg CBD twice daily over 4 weeks. After 8 weeks of treatment, the patient reported a reduction in burning sensation from NRS 8/10 to 4/10, with concurrent improvement in xerostomia and taste alterations. Pain relief was maintained at 6-month follow-up with stable dosing and no significant adverse effects. This case suggests that CBD-dominant cannabis preparations may offer a promising therapeutic option for BMS through modulation of the endo- cannabinoid system.

Cite this paper

Gentili, L. , Scimia, P. , Nania, F. and Angeletti, C. (2025). Targeting the Endocannabinoid System in Burning Mouth Syndrome: A Case Report on CBD-Dominant Cannabis Oil. Open Access Library Journal, 12, e3432. doi: http://dx.doi.org/10.4236/oalib.1113432.

References

[1]  Alsabbagh, R. and Ouanounou, A. (2022) Burning Mouth Syndrome: Etiology, Clinical Presentations, and Treatment Alter-natives. Dentistry Review, 2, Article 100036. https://doi.org/10.1016/j.dentre.2022.100036
[2]  ICOP Classification Committee (2020) International Classification of Orofacial Pain, 1st Edition. Cephalalgia, 40, 129-221.
[3]  Tan, H.L. and Renton, T. (2020) Burning Mouth Syndrome: An Update. Cephalalgia Reports, 3. https://doi.org/10.1177/2515816320970143
[4]  Pereira, S.R., Velasquez, J.T., Duggan, S., Ivanisevic, B., McKenna, J.P., McCreary, C., et al. (2020) Recent Advances in the Understanding of the Aetiology and Therapeutic Strategies in Burning Mouth Syndrome: Focus on the Actions of Cannabinoids. European Journal of Neuroscience, 55, 1032-1050. https://doi.org/10.1111/ejn.14712
[5]  Imamura, Y., Shinozaki, T., Okada‐Ogawa, A., Noma, N., Shinoda, M., Iwata, K., et al. (2019) An Updated Review on Pathophysiology and Management of Burning Mouth Syndrome with Endocrinological, Psychological and Neuropathic Perspectives. Journal of Oral Rehabilitation, 46, 574-587. https://doi.org/10.1111/joor.12795
[6]  Borsani, E., Majorana, A., Cocchi, M.A., Conti, G., Bonadeo, S., Padovani, A., et al. (2014) Epithelial Expression of Vanilloid and Cannabinoid Receptors: A Potential Role in Burning Mouth Syndrome Patho-genesis. Histology and Histopathology, 29, 523-533.
[7]  Yilmaz, Z., Renton, T., Yiangou, Y., Zakrzewska, J., Chessell, I.P., Bountra, C., et al. (2007) Burning Mouth Syndrome as a Trigeminal Small Fibre Neuropathy: Increased Heat and Capsaicin Receptor TRPV1 in Nerve Fibres Correlates with Pain Score. Journal of Clinical Neuroscience, 14, 864-871. https://doi.org/10.1016/j.jocn.2006.09.002
[8]  Beneng, K., Yilmaz, Z., Yiangou, Y., McParland, H., Anand, P. and Ren-ton, T. (2010) Sensory Purinergic Receptor P2X3 Is Elevated in Burning Mouth Syndrome. International Journal of Oral and Maxillofacial Surgery, 39, 815-819. https://doi.org/10.1016/j.ijom.2010.03.013
[9]  Gambino, A., Cabras, M., Panagio-takos, E., Calvo, F., Macciotta, A., Cafaro, A., et al. (2020) Evaluating the Suitability and Potential Efficiency of cannabis Sa-tiva Oil for Patients with Primary Burning Mouth Syndrome: A Prospective, Open-Label, Single-Arm Pilot Study. Pain Medi-cine, 22, 142-151. https://doi.org/10.1093/pm/pnaa318
[10]  Gremeau-Richard, C., Woda, A., Navez, M.L., Attal, N., Bouhassira, D., Gagnieu, M.C., et al. (2004) Topical Clonazepam in Stomatodynia: A Randomised Placebo-Controlled Study. Pain, 108, 51-57. https://doi.org/10.1016/j.pain.2003.12.002
[11]  McMillan, R., Forssell, H., Buchanan, J.A., Glenny, A., Weldon, J.C. and Zakrzewska, J.M. (2016) Interventions for Treating Burning Mouth Syndrome. Cochrane Database of Sys-tematic Reviews, No. 11, CD002779. https://doi.org/10.1002/14651858.cd002779.pub3
[12]  Liu, Y., Kim, Y., Yoo, T., Han, P. and Inman, J. (2017) Burning Mouth Syndrome: A Systematic Review of Treatments. Oral Diseases, 24, 325-334. https://doi.org/10.1111/odi.12660
[13]  Marzo, V.D., Bifulco, M. and Petrocellis, L.D. (2004) The Endocannabinoid Sys-tem and Its Therapeutic Exploitation. Nature Reviews Drug Discovery, 3, 771-784. https://doi.org/10.1038/nrd1495
[14]  Mücke, M., Phillips, T., Radbruch, L., Petzke, F. and Häuser, W. (2018) Canna-bis-based Medicines for Chronic Neuropathic Pain in Adults. Cochrane Database of Systematic Reviews, No. 3, CD012182. https://doi.org/10.1002/14651858.cd012182.pub2
[15]  Russo, E. (2008) Cannabinoids in the Management of Difficult to Treat Pain. Therapeutics and Clinical Risk Management, 4, 245-259. https://doi.org/10.2147/tcrm.s1928
[16]  Häuser, W., Finn, D.P., Kalso, E., Krcevski‐Skvarc, N., Kress, H., Morlion, B., et al. (2018) European Pain Federation (EFIC) Position Paper on Appropriate Use of Cannabis‐Based Medicines and Medical Cannabis for Chronic Pain Management. European Journal of Pain, 22, 1547-1564. https://doi.org/10.1002/ejp.1297
[17]  Barry, A., O’Halloran, K.D., McKenna, J.P., McCreary, C., Harhen, B., Kerr, D.M., et al. (2018) Plasma N‐Acylethanolamine and Endocannabinoid Levels in Burning Mouth Syndrome: Potential Role in Disease Pathogenesis. Journal of Oral Pathology & Medicine, 47, 440-442. https://doi.org/10.1111/jop.12692

Full-Text


Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133